Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
Inside the Cheapest Gold Bullion ETF

12h zacks
As competition is intensifying in the ETF space, lower fees are gaining prominence as a tool to attract investors. For a long period of time, the lowest cost corner of the market was dominated by Charles Schwab and Vanguard.
GLDM SCHW.PRBCL STT BAR STT.PRC O87 STT.PRE STT.PRD STT.PRG GLD IAU

5
U.S. Bancorp (USB) to Report Q2 Earnings: What's in Store?

19h zacks
U.S. Bancorp (USB - Free Report) is scheduled to report second-quarter 2018 results on Jul 18, before the opening bell. The bank’s revenues and earnings are anticipated to reflect year-over-year growth. Benefits of higher rates and improved lending scenario are anticipated to have offset the muted trading performance. The Zacks Consensus Estimate for sales of $5.6 billion reflects a rise of 3.7% from the year-ago quarter.
STT STI.WS.B STI.WS.A STT.PRC NTRSP STT.PRE STT.PRD STT.PRG USB STI NTRS GTT STI-A STI.PRE CFR

3
Netflix: After The Close

21h seekingalpha
Netflix has a huge presence in passive investing, ETFG's equity exposure reports shed light on potential movement within ETFs.
NEWR HD STT STT.PRC STT.PRE STT.PRD SPY STT.PRG NFLX FDN XLC

78
3 Big Stock Charts for Monday: State Street, Cisco and Walmart | InvestorPlace

22h investorplace
The bulls were charging with a vengeance when Friday’s action started, but by the time the closing bell rang, stocks barely managed to remain in the black. There were more losers than winners on Friday.
STT GE GEC STT.PRC STT.PRE STT.PRD STT.PRG AMD NYTAB WMT AMZN CSCO GNE

4
U.S. Airlines: Ready For Re-Rating

2018-07-14 seekingalpha
Bill Miller, the famed value investor, imagines a new normal in which airlines remain profitable during recessions. If the airlines show they can withstand the next downturn, Miller says, it could lead to a significant re-rating in which investors price airline stocks more like industrial stocks - in other words, at twice the price where they currently trade.
BRK.A STT STT.PRC STT.PRE STT.PRD STT.PRG

1
Emerging-Market Investors May Want to Skip Next Month - Bloomberg

2018-07-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
STT STT.PRC STT.PRE STT.PRD STT.PRG

50
PNC Financial (PNC) Q2 Earnings Beat Estimates, Revenues Up

2018-07-13 zacks
Riding on high revenues, The PNC Financial Services Group (PNC - Free Report) delivered a positive earnings surprise of 5.4% in second-quarter 2018. Earnings per share of $2.72 beat the Zacks Consensus Estimate of $2.58. Moreover, the bottom line reflected a 30% increase from the prior-year quarter.
STT BAC STT.PRC CMA PNC.PRP STT.PRE PNC.PRQ STT.PRD STT.PRG PNCFO BAC PNC.WS PNC PNUCL

2
Why an Earnings Beat is Likely for Comerica (CMA) in Q2

2018-07-13 zacks
Comerica Incorporated (CMA - Free Report) is scheduled to report second-quarter 2018 results before the opening bell on Jul 17. Its revenues and earnings are expected to grow year over year.
STT CMA.WS STT.PRC CMA STT.PRE STT.PRD BKU STT.PRG KEY SAM CMPWW

1
EMERGING MARKETS-China soothes shares, lira limps to worst week since 2008

2018-07-13 reuters
LONDON, July 13 (Reuters) - Emerging market shares edged toward their first weekly gain in over a month on Friday, though there was some serious damage showing, including the worst week for Turkey’s lira since the financial crisis a decade ago.
STT STT.PRC STT.PRE STT.PRD STT.PRG

11
BASI / Bioanalytical Systems, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-13 fintel.io
This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
BASI STT DB STT.PRC STT.PRE STT.PRD STT.PRG CATB

35
S / Sprint Corporation - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-12 fintel.io
Sprint Corporation (NYSE:S) has 717 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,964,750,410 shares. Largest shareholders include Softbank Group Corp, Dodge & Cox, Ontario Teachers Pension Plan Board, BlackRock Inc., Vanguard Group Inc, Primecap Management Co/ca/, Odey Asset Management Group Ltd, State Street Corp, Norges Bank, and MIG Capital, LLC.
STT BLK S STT.PRC STT.PRE STT.PRD STT.PRG SFTBF 9984 SFTBY

1
BMS / Bemis Co., Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-10 fintel.io
Bemis Co., Inc. (NYSE:BMS) has 352 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 77,084,551 shares. Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, American Century Companies Inc, Mairs & Power INC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.
STT BLK BMS STT.PRC STT.PRE STT.PRD STT.PRG

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

5h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...